An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer
- 1 June 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 19 (6), 1373-1382
- https://doi.org/10.1158/1535-7163.mct-19-0531
Abstract
Prostate cancer (PC) patients with tumors harboring defects in DNA-repair genes (DRD) generally do not respond well to AR-directed therapy. Furthermore, canonical pathways evolve during disease progression and may impact treatment with existing therapies. Due to the limited treatment options after failure of hormonal and taxane therapy, and the tumor heterogeneity induced by DRD, we sought to characterize the alterations in primary and metastatic PC. Tumors from 1027 advanced PC patients that underwent comprehensive genomic profiling for routine clinical care were reviewed to assess DRD mutation rates (27 gene panel) and co-occurring mutations in select canonical PC pathways. DRD alterations were identified in 20 genes and in 17% of patients (BRCA2 and ATM most common) occurring with slightly higher frequency in specimens from metastatic biopsy sites and men older than 50 years of age. MSI-H and TMB-H occurred with 3% frequency in the overall cohort but were not enriched in metastatic disease. Biomarkers previously associated with anti-tumor immunity are found at high frequencies in MSI-H patients, including JAK1 (68%) and PTEN (32%). Lastly, mutations in TP53, AR, PTEN, APC, CTNNB1 and PIK3CA were all significantly enriched in metastatic samples. We identified clinically significant subgroups of patients demonstrating (1) defects in DNA repair pathways, (2) intrinsic PC signaling pathways that may prevent anti-tumor immunity and (3) distinct genomic differences between localized and metastatic PC. These results lend support that genomic profiling for advanced PC may identify actionable targets not routinely used in the current metastatic paradigm.Other Versions
Funding Information
- Caris Life Sciences (n/a)
This publication has 44 references indexed in Scilit:
- Risk of Prostate Cancer in Lynch Syndrome: A Systematic Review and Meta-analysisCancer Epidemiology, Biomarkers & Prevention, 2014
- Distribution of metastatic sites in patients with prostate cancer: A population‐based analysisThe Prostate, 2013
- DNA repair dysregulation from cancer driver to therapeutic targetNature Reviews Cancer, 2012
- The complexity of prostate cancer: genomic alterations and heterogeneityNature Reviews Urology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Wnt Signaling in CancerCold Spring Harbor Perspectives in Biology, 2012
- Decreased Prostate Cancer-Specific Survival of Men with BRCA2 Mutations from Multiple Breast Cancer FamiliesCancer Prevention Research, 2011
- Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate CancerCancer Epidemiology, Biomarkers & Prevention, 2009
- Heterozygous ATR Mutations in Mismatch Repair–Deficient Cancer Cells Have Functional SignificanceCancer Research, 2005
- Wnt signalling and prostate cancerProstate Cancer and Prostatic Diseases, 2005